Development of therapeutic antibodies for the treatment of diseases
Abstract Since the first monoclonal antibody drug, muromonab-CD3, was approved for marketing in 1986, 165 antibody drugs have been approved or are under regulatory review worldwide. With the approval of new drugs for treating a wide range of diseases, including cancer and autoimmune and metabolic di...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2022-11-01
|
| Series: | Molecular Biomedicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43556-022-00100-4 |
| _version_ | 1811211169028898816 |
|---|---|
| author | Zeng Wang Guoqing Wang Huaqing Lu Hongjian Li Mei Tang Aiping Tong |
| author_facet | Zeng Wang Guoqing Wang Huaqing Lu Hongjian Li Mei Tang Aiping Tong |
| author_sort | Zeng Wang |
| collection | DOAJ |
| description | Abstract Since the first monoclonal antibody drug, muromonab-CD3, was approved for marketing in 1986, 165 antibody drugs have been approved or are under regulatory review worldwide. With the approval of new drugs for treating a wide range of diseases, including cancer and autoimmune and metabolic disorders, the therapeutic antibody drug market has experienced explosive growth. Monoclonal antibodies have been sought after by many biopharmaceutical companies and scientific research institutes due to their high specificity, strong targeting abilities, low toxicity, side effects, and high development success rate. The related industries and markets are growing rapidly, and therapeutic antibodies are one of the most important research and development areas in the field of biology and medicine. In recent years, great progress has been made in the key technologies and theoretical innovations provided by therapeutic antibodies, including antibody–drug conjugates, antibody-conjugated nuclides, bispecific antibodies, nanobodies, and other antibody analogs. Additionally, therapeutic antibodies can be combined with technologies used in other fields to create new cross-fields, such as chimeric antigen receptor T cells (CAR-T), CAR-natural killer cells (CAR-NK), and other cell therapy. This review summarizes the latest approved or in regulatory review therapeutic antibodies that have been approved or that are under regulatory review worldwide, as well as clinical research on these approaches and their development, and outlines antibody discovery strategies that have emerged during the development of therapeutic antibodies, such as hybridoma technology, phage display, preparation of fully human antibody from transgenic mice, single B-cell antibody technology, and artificial intelligence-assisted antibody discovery. |
| first_indexed | 2024-04-12T05:08:13Z |
| format | Article |
| id | doaj.art-4d6bad5f12cb4a0b851ba096e6ad6ce6 |
| institution | Directory Open Access Journal |
| issn | 2662-8651 |
| language | English |
| last_indexed | 2024-04-12T05:08:13Z |
| publishDate | 2022-11-01 |
| publisher | Springer |
| record_format | Article |
| series | Molecular Biomedicine |
| spelling | doaj.art-4d6bad5f12cb4a0b851ba096e6ad6ce62022-12-22T03:46:50ZengSpringerMolecular Biomedicine2662-86512022-11-013113110.1186/s43556-022-00100-4Development of therapeutic antibodies for the treatment of diseasesZeng Wang0Guoqing Wang1Huaqing Lu2Hongjian Li3Mei Tang4Aiping Tong5State Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan UniversityDepartment of Neurosurgery, West China Medical School, West China Hospital, Sichuan UniversityState Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan UniversityInstitute for Immunology and School of Medicine, Tsinghua UniversityState Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan UniversityState Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan UniversityAbstract Since the first monoclonal antibody drug, muromonab-CD3, was approved for marketing in 1986, 165 antibody drugs have been approved or are under regulatory review worldwide. With the approval of new drugs for treating a wide range of diseases, including cancer and autoimmune and metabolic disorders, the therapeutic antibody drug market has experienced explosive growth. Monoclonal antibodies have been sought after by many biopharmaceutical companies and scientific research institutes due to their high specificity, strong targeting abilities, low toxicity, side effects, and high development success rate. The related industries and markets are growing rapidly, and therapeutic antibodies are one of the most important research and development areas in the field of biology and medicine. In recent years, great progress has been made in the key technologies and theoretical innovations provided by therapeutic antibodies, including antibody–drug conjugates, antibody-conjugated nuclides, bispecific antibodies, nanobodies, and other antibody analogs. Additionally, therapeutic antibodies can be combined with technologies used in other fields to create new cross-fields, such as chimeric antigen receptor T cells (CAR-T), CAR-natural killer cells (CAR-NK), and other cell therapy. This review summarizes the latest approved or in regulatory review therapeutic antibodies that have been approved or that are under regulatory review worldwide, as well as clinical research on these approaches and their development, and outlines antibody discovery strategies that have emerged during the development of therapeutic antibodies, such as hybridoma technology, phage display, preparation of fully human antibody from transgenic mice, single B-cell antibody technology, and artificial intelligence-assisted antibody discovery.https://doi.org/10.1186/s43556-022-00100-4ImmunotherapyAntibody drugsPhage display librariesTransgenic miceSingle B-cellAI-assisted antibody discovery |
| spellingShingle | Zeng Wang Guoqing Wang Huaqing Lu Hongjian Li Mei Tang Aiping Tong Development of therapeutic antibodies for the treatment of diseases Molecular Biomedicine Immunotherapy Antibody drugs Phage display libraries Transgenic mice Single B-cell AI-assisted antibody discovery |
| title | Development of therapeutic antibodies for the treatment of diseases |
| title_full | Development of therapeutic antibodies for the treatment of diseases |
| title_fullStr | Development of therapeutic antibodies for the treatment of diseases |
| title_full_unstemmed | Development of therapeutic antibodies for the treatment of diseases |
| title_short | Development of therapeutic antibodies for the treatment of diseases |
| title_sort | development of therapeutic antibodies for the treatment of diseases |
| topic | Immunotherapy Antibody drugs Phage display libraries Transgenic mice Single B-cell AI-assisted antibody discovery |
| url | https://doi.org/10.1186/s43556-022-00100-4 |
| work_keys_str_mv | AT zengwang developmentoftherapeuticantibodiesforthetreatmentofdiseases AT guoqingwang developmentoftherapeuticantibodiesforthetreatmentofdiseases AT huaqinglu developmentoftherapeuticantibodiesforthetreatmentofdiseases AT hongjianli developmentoftherapeuticantibodiesforthetreatmentofdiseases AT meitang developmentoftherapeuticantibodiesforthetreatmentofdiseases AT aipingtong developmentoftherapeuticantibodiesforthetreatmentofdiseases |